Pharmaceutical composition
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is related to pharmaceutical compositions for the inhibition of metastases and treatment of cancer such as bladder carcinoma, colon cancer, endometrial cancer, hepatocellular carcinoma, leukemia, lymphoma, melanoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, soft tissue cancer, renal cancer, osteosarcoma, mesothelioma, myeloma multiple, bladder carcinoma and esophagcal cancer as well as the use of these pharmaceutical compositions for the treatment of said metastases and cancers. Another aspect of this invention are new antisense oligonucleotides inhibiting the formation of human interleukin 10 and their synthesis. A further aspect of this invention is the use IL-10 antisense oligonucleotides for the preparation of pharmaceutical compositions and for the treatment of cancer and metastases.
-
Citations
45 Claims
-
1-22. -22. (canceled)
- 23. A method for cancer treatment comprising the step of administering at least one oligonucleotide or its active derivative to a subject, wherein said at least one oligonucleotide or its active derivative inhibits the formation of metastases in said subject.
- 30. A method for cancer treatment comprising the step of administering at least one oligonucleotide or its active derivative to a subject, wherein said at least one oligonucleotide or its active derivative inhibits the formation of metastases in said subject and said cancer is selected from the group consisting of prostate cancer, bladder carcinoma, colon cancer, endometrial cancer, hepatocellular carcinoma, leukemia, lymphoma, melanoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer or is selected from the group of melanoma, renal cancer, leukaemia, lymphoma, osteosarcoma, mesothelioma, myeloma multiple and bladder cancer.
-
34. An antisense-oligonucleotide or its active derivative, selected from the group consisting of IL-10 antisense oligonucleotides identified in the sequence listing under Seq. ID. NO 49 to 68 or identified in example 22.
-
36. A process of manufacturing an antisense oligonucleotide or its active derivative by phosphite triester chemistry in which said nucleotide chain grows in 3′
- to 5′
direction and each consecutive nucleotide is coupled to a first nucleotide that is covalently attached to a solid phase, comprising the steps ofcleaving the 5′
DMT protecting group of each consecutive nucleotide,adding a consecutive nucleotide for chain prolongation, modifying phosphite groups, capping unreacted 5′
-hydroxyl groups,cleaving said oligonucleotides from said solid support. - View Dependent Claims (37)
- to 5′
-
38. A Pharmaceutical composition comprising an antisense oligonucleotide as identified in the sequence listing under Seq. ID. NO 49 to 68 or as identified in example 22.
- 39. A method for cancer treatment comprising the step of administering a TGF-beta 2 antagonist to a subject, wherein said cancer is selected from the group consisting of colon cancer, prostate cancer, melanoma, endometrial cancer, bladder cancer, ovarian cancer, pancreas cancer and mesothelioma.
-
42. A method for cancer treatment comprising the step of administering a TGF-beta 2 antagonist to a subject, wherein said cancer is selected from the group consisting of colon cancer, prostate cancer, melanoma, endometrial cancer, bladder cancer, ovarian cancer, pancreas cancer and mesothelioma.
-
43. A method for cancer treatment comprising the step of administering at least one oligonucleotide or its active derivative to a subject, wherein said at least one oligonucleotide or its active derivative treats metastases of said tumor.
- 44. A method for cancer metastase treatment comprising the step of administering at least one oligonucleotide or its active derivative to a subject, wherein said cancer is selected from the group consisting of colon cancer, prostate cancer, melanoma, bladder cancer, endometrial cancer, esophageal cancer, hepatocellular cancer, non-small-cell lung cancer, ovarian cancer, osteosarcoma, mesothelioma, renal cancer, myeloma multiple, pancreas carcinoma, leukaemia, lymphoma and soft tissue cancer.
Specification